Taking A Deep Dive into Precision Medicine for Obstructive Hypertrophic Cardiomyopathy

James L. Januzzi, MD, provides insight on the pathophysiology of obstructive hypertrophic cardiomyopathy (oHCM) and comments on small-molecule myosin inhibitors as an emerging therapeutic option.

An expert cardiologist examines unmet needs and bridging the gap in care for patients with oHCM.

Dr James L. Januzzi reviews the use of cardiac myosin inhibitors for the management of oHCM.

An expert in cardiology shares clinical trial findings of emerging and approved cardiac myosin inhibitors for the treatment of oHCM.

James L. Januzzi, MD, comments on mavacamten as the first approved cardiac myosin inhibitor for oHCM, balancing the increased risk of heart failure with the medication, and the role of the REMS program.

An expert cardiologist discusses the importance of healthcare provider education and finding resources around the REMS program.